COVID-19 in kidney transplant recipients.
Aged
Betacoronavirus
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques
Coronavirus Infections
/ complications
Critical Care
Electronic Health Records
Female
Hospitalization
Humans
Immunocompromised Host
Immunosuppression Therapy
/ adverse effects
Kidney Failure, Chronic
/ complications
Kidney Transplantation
Male
Middle Aged
New York
/ epidemiology
Pandemics
Pneumonia, Viral
/ complications
SARS-CoV-2
Transplant Recipients
clinical research/practice
infection and infectious agents - viral
kidney (allograft) function/dysfunction
kidney transplantation/nephrology
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
02
04
2020
revised:
22
04
2020
accepted:
25
04
2020
pubmed:
1
5
2020
medline:
21
7
2020
entrez:
1
5
2020
Statut:
ppublish
Résumé
There is minimal information on coronavirus disease 2019 (COVID-19) in immunocompromised individuals. We have studied 10 patients treated at 12 adult care hospitals. Ten kidney transplant recipients tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by polymerase chain reaction, and 9 were admitted. The median age was 57 (interquartile range [IQR] 47-67), 60% were male, 40% Caucasian, and 30% Black/African American. Median time from transplant to COVID-19 testing was 2822 days (IQR 1272-4592). The most common symptom was fever, followed by cough, myalgia, chills, and fatigue. The most common chest X-ray and computed tomography abnormality was multifocal patchy opacities. Three patients had no abnormal findings. Leukopenia was seen in 20% of patients, and allograft function was stable in 50% of patients. Nine patients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone. Hospitalized patients had their antimetabolite agent stopped. All hospitalized patients received hydroxychloroquine and azithromycin. Three patients died (30%), and 5 (50%) developed acute kidney injury. Kidney transplant recipients infected with COVID-19 should be monitored closely in the setting of lowered immunosuppression. Most individuals required hospitalization and presenting symptoms were similar to those of nontransplant individuals.
Identifiants
pubmed: 32351040
doi: 10.1111/ajt.15967
pmc: PMC7267603
pii: S1600-6135(22)22417-4
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1819-1825Subventions
Organisme : NIA NIH HHS
ID : R24 AG064191
Pays : United States
Organisme : NLM NIH HHS
ID : R01 LM012836
Pays : United States
Organisme : U.S. National Library of Medicine
ID : R01LM012836
Pays : International
Organisme : NHLBI NIH HHS
ID : K23 HL145114
Pays : United States
Organisme : NIA NIH HHS
ID : R24AG064191
Pays : United States
Informations de copyright
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670
pubmed: 32196083
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
N Engl J Med. 2020 Mar 26;382(13):1268-1269
pubmed: 32109011
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Kidney Int Rep. 2020 Apr 04;5(5):580-585
pubmed: 32292866
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Int J Antimicrob Agents. 2020 May;55(5):105938
pubmed: 32171740
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am J Transplant. 2020 Jul;20(7):1859-1863
pubmed: 32181990
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Eur Urol. 2020 Jun;77(6):742-747
pubmed: 32249089
Am J Transplant. 2020 Jul;20(7):1875-1878
pubmed: 32198834
Drug Discov Ther. 2019;13(6):314-321
pubmed: 31956229